{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:36Z","timestamp":1786982376159,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s12325-008-0085-z","type":"journal-article","created":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T19:56:37Z","timestamp":1218657397000},"page":"725-742","source":"Crossref","is-referenced-by-count":48,"title":["Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload"],"prefix":"10.1007","volume":"25","author":[{"given":"Krista A.","family":"Payne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rofail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Baladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Viala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Abetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Desrosiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"Lordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khajak","family":"Ishak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Proskorovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,8,14]]},"reference":[{"key":"85_CR1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","volume":"89","author":"N.F. Olivieri","year":"1997","unstructured":"Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739\u2013761.","journal-title":"Blood."},{"key":"85_CR2","unstructured":"Harvard Medical School. Effects of iron overload: hemochromatosis, tranfusional iron overload. 2006. Available at: http:\/\/sickle.bwh.harvard.edu\/index.html . Accessed June 2008."},{"key":"85_CR3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","volume":"95","author":"V. Gabutti","year":"1996","unstructured":"Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26\u201336.","journal-title":"Acta Haematol."},{"key":"85_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7748\/paed.10.3.17.s19","volume":"10","author":"V. Vidler","year":"1998","unstructured":"Vidler V. Compliance with iron chelation therapy in beta thalassaemia. Paediatr Nurs. 1998;10:17\u201318.","journal-title":"Paediatr Nurs."},{"issue":"suppl5","key":"85_CR5","first-page":"122","volume":"75","author":"P. Rebulla","year":"1990","unstructured":"Rebulla P. Transfusion reactions in thalassemia. A survey from the Cooleycare programme. The Cooleycare Cooperative Group. Haematologica. 1990;75(suppl 5): 122\u2013127.","journal-title":"Haematologica."},{"key":"85_CR6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0037-1963(01)90030-7","volume":"38","author":"P.J. Giardina","year":"2001","unstructured":"Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol. 2001;38:360\u2013366.","journal-title":"Semin Hematol."},{"key":"85_CR7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.thj.6200550","volume":"5","author":"V. Alymara","year":"2004","unstructured":"Alymara V, Bourantas D, Chaidos A, et al. Effectiveness and safety of combined ironchelation therapy with deferoxamine and deferiprone. Hematol J. 2004;5:475\u2013479.","journal-title":"Hematol J."},{"key":"85_CR8","volume-title":"The International Assessment of HRQL. Theory, Translations, Measurement and Analysis","author":"S.A. Shumaker","year":"1995","unstructured":"Shumaker SA, Berzon RA. The International Assessment of HRQL. Theory, Translations, Measurement and Analysis. Oxford: Rapid Communications; 1995."},{"key":"85_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7525-4-73","volume":"4","author":"L. Abetz","year":"2006","unstructured":"Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes. 2006;4:73.","journal-title":"Health Qual Life Outcomes"},{"key":"85_CR10","first-page":"533","volume":"95","author":"S.P. Hasan","year":"2003","unstructured":"Hasan SP, Hashmi S, Alhassen M, et al. Depression in sickle cell disease. J Natl Med Assoc. 2003;95:533\u2013537.","journal-title":"J Natl Med Assoc."},{"key":"85_CR11","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","volume":"20","author":"A.B. Kornblith","year":"2002","unstructured":"Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441\u20132452.","journal-title":"J Clin Oncol."},{"key":"85_CR12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","volume":"339","author":"N. Olivieri","year":"1998","unstructured":"Olivieri N, Brittenham GM, McLaren CE, et al. Long-term safety and effectivness of iron chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417\u2013423.","journal-title":"N Engl J Med."},{"key":"85_CR13","first-page":"4","volume":"2","author":"J.J. Caro","year":"2002","unstructured":"Caro JJ, Huybrechts K, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared to subcutaneous desferrioxamine for treatment of iron overload in thalassaemia major: a systematic review. BMC Blood Disord. 2002;2:4.","journal-title":"BMC Blood Disord."},{"key":"85_CR14","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/j.1537-2995.2007.01398.x","volume":"47","author":"K.A. Payne","year":"2007","unstructured":"Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy (ICT) in the United States. Transfusion. 2007;47:1820\u20131829.","journal-title":"Transfusion."},{"key":"85_CR15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(97)07330-3","volume":"350","author":"G.R. Serjeant","year":"1997","unstructured":"Serjeant GR. Sickle-cell disease. Lancet. 1997;350:725\u2013730.","journal-title":"Lancet."},{"key":"85_CR16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMp048266","volume":"352","author":"M. Cazzola","year":"2005","unstructured":"Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536\u2013538.","journal-title":"N Engl J Med."},{"key":"85_CR17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"J.E. Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473\u2013483.","journal-title":"Med Care."},{"key":"85_CR18","doi-asserted-by":"crossref","unstructured":"Rofail D, Abetz L, Viala M, et al. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed questionnaire. Value Health. 2008; Jul 11. Epub ahead of print.","DOI":"10.1016\/S1098-3015(10)67103-3"},{"key":"85_CR19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0895-4356(98)00103-6","volume":"51","author":"J. Brazier","year":"1998","unstructured":"Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51:1115\u20131128.","journal-title":"J Clin Epidemiol."},{"key":"85_CR20","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost Effectiveness in Health and Medicine","author":"M.R. Gold","year":"1996","unstructured":"Gold MR, Siegel JE, Russell LB, Weistein MC. Cost Effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996."},{"key":"85_CR21","first-page":"1","volume":"3","author":"D. Zeuner","year":"1999","unstructured":"Zeuner D, Ades A, Karnon J, et al. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. NHS Health Technol Assess Prog. 1999;3:1\u2013186.","journal-title":"NHS Health Technol Assess Prog."},{"key":"85_CR22","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood.V96.7.2369","volume":"96","author":"A. Wayne","year":"2000","unstructured":"Wayne A, Schoenike S, Pegelow C, et al. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood. 2000;96:2367\u20132369.","journal-title":"Blood."},{"key":"85_CR23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1365-2257.1999.00262.x","volume":"21","author":"J. Karnon","year":"1992","unstructured":"Karnon J, Zeuner D, Brown J, et al. Lifetime treatment cost of beta-thalassemia major. Clin Lab Haem. 1992;21:377\u2013385.","journal-title":"Clin Lab Haem."},{"key":"85_CR24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/jms.5.3.120","volume":"5","author":"G. Ginsberg","year":"1998","unstructured":"Ginsberg G, Tulchinsky T, Filon D, et al. Cost-benefit analysis of a national thalassemia prevention programme in Israel. J Med Screen. 1998;5:120\u2013126.","journal-title":"J Med Screen."},{"key":"85_CR25","unstructured":"Jenkinson C, Stewart-Brown S, Petersen S. Assessment and Evaluation of the SF36 Version II. Health Services Research Unit: University of Oxford; 2006. Available at: www.hsru.ox.ac.uk\/sf36v2.htm. Accessed 9 February 2006."},{"key":"85_CR26","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/j.1523-1755.2005.00752.x","volume":"68","author":"I. Gorodetskaya","year":"2005","unstructured":"Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801\u20132808.","journal-title":"Kidney Int."},{"key":"85_CR27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J. Brazier","year":"2001","unstructured":"Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2001;21:271\u2013292.","journal-title":"J Health Econ."},{"key":"85_CR28","volume-title":"The Child Health Questionnaire (CHQ): a User\u2019s Manual","author":"J.M. Landgraf","year":"1996","unstructured":"Landgraf JM, Abetz L, Ware JE. The Child Health Questionnaire (CHQ): a User\u2019s Manual. 2nd ed. Boston, MA: The Health Institute; 1996.","edition":"2"},{"key":"85_CR29","unstructured":"Medi-Scot web site. Available at: www.mediscot.co.uk. Accessed 18 September 2006."},{"key":"85_CR30","unstructured":"Medicines and Healthcare Products Regulatory Agency. Market survey. Nonelectrically powered dispoable infusion devices. Report 05055. September 2005. Available at: www.pasa.nhs.uk\/evaluation\/docs\/general_medical\/Report_05055 pdf. Accessed 23 October 2006."},{"key":"85_CR31","unstructured":"Williams Medical Supplies. Available at: www wmsplc.co.uk. Accessed 18 September 2006."},{"key":"85_CR32","volume-title":"Guidelines for the control of haemoglobin disorders. Report of the Sixth Annual Meeting of the WHO Working Group on Haemoglobinopathies, Cagliari, Sardinia, 8\u20139 April 1989","author":"B. Modell","year":"2004","unstructured":"Modell B. Guidelines for the control of haemoglobin disorders. Report of the Sixth Annual Meeting of the WHO Working Group on Haemoglobinopathies, Cagliari, Sardinia, 8\u20139 April 1989. Geneva: World Health Organization; 2004."},{"key":"85_CR33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.20103","volume":"76","author":"G.C. Chan","year":"2004","unstructured":"Chan GC, Ng DM, Fong DY, et al. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model. Am J Hematol. 2004;76:398\u2013404.","journal-title":"Am J Hematol."},{"key":"85_CR34","doi-asserted-by":"crossref","unstructured":"Curtis L, Netten A. Unit Costs of Health and Social Care 2005. The University of Kent, Personal Social Services Research Unit 202.","DOI":"10.46692\/9781847421302.006"},{"key":"85_CR35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","volume":"331","author":"N.F. Olivieri","year":"1994","unstructured":"Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta thalassemia. N Engl J Med. 1994;331:574\u2013578.","journal-title":"N Engl J Med."},{"key":"85_CR36","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1046\/j.1365-2141.2000.02298.x","volume":"110","author":"P.T. Telfer","year":"2000","unstructured":"Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971\u2013977.","journal-title":"Br J Haematol."},{"key":"85_CR37","first-page":"1187","volume":"89","author":"C. Borgna-Pignatti","year":"2004","unstructured":"Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187\u20131193.","journal-title":"Haematologica"},{"key":"85_CR38","unstructured":"Thalassemia International Federation web site. Guidelines for Clinical Management of Thalassemia. 2000. Available at: www. thalassaemia.org.cy\/MyData\/Books\/Clinical_%20Management_Thalassaemia.pdf. Accessed June 2008."},{"key":"85_CR39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s002280000251","volume":"56","author":"R. Arboretti","year":"2001","unstructured":"Arboretti R, Tognoni G, Alberti D. Italian Collaborative Group on Thalassarmia. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol. 2001;56:915\u2013922.","journal-title":"Eur J Clin Pharmacol."},{"key":"85_CR40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1600-0609.2001.067001030.x","volume":"67","author":"A. Taher","year":"2001","unstructured":"Taher A, Sheikh-Taha M, Koussa S, et al. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol. 2001;67:30\u201334.","journal-title":"Eur J Haematol."},{"key":"85_CR41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000057633","volume":"107","author":"J.J. Caro","year":"2002","unstructured":"Caro JJ, Ward A, Green TC, et al. Impact of thalassemia major on patients and their families. Acta Haematol. 2002;107: 150\u2013157.","journal-title":"Acta Haematol."},{"key":"85_CR42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6904-2-3","volume":"2","author":"A. Ward","year":"2002","unstructured":"Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol. 2002;2:3.","journal-title":"BMC Clin Pharmacol."},{"key":"85_CR43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2003-09-3167","volume":"104","author":"M.J. Cunningham","year":"2004","unstructured":"Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of betathalassemia major in North America. Blood. 2004;104:34\u201339.","journal-title":"Blood."},{"key":"85_CR44","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","volume":"43","author":"M. Kosinski","year":"2000","unstructured":"Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43:1478\u20131487.","journal-title":"Arthritis Rheum."},{"key":"85_CR45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00019053-199915020-00003","volume":"15","author":"G. Samsa","year":"1999","unstructured":"Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999;15: 141\u2013155.","journal-title":"Pharmacoeconomics."},{"key":"85_CR46","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0277-9536(91)90025-8","volume":"33","author":"J.J. Williams","year":"1991","unstructured":"Williams JJ, Calnan M. Convergence and divergence: assessing criteria of consumer satisfaction across general practice, dental, and hospital care settings. Soc Sci Med. 1991;33:707\u2013716.","journal-title":"Soc Sci Med."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-008-0085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-008-0085-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-008-0085-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:17:03Z","timestamp":1709180223000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-008-0085-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1007\/s12325-008-0085-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}